Biomarin Pharmaceutical Inc (BMRN) - Total Assets
Based on the latest financial reports, Biomarin Pharmaceutical Inc (BMRN) holds total assets worth $8.59 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore BMRN operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Biomarin Pharmaceutical Inc - Total Assets Trend (1998–2025)
This chart illustrates how Biomarin Pharmaceutical Inc's total assets have evolved over time, based on quarterly financial data. See BMRN net assets for net asset value and shareholders' equity analysis.
Biomarin Pharmaceutical Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Biomarin Pharmaceutical Inc's total assets of $8.59 Billion consist of 52.1% current assets and 47.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.3% |
| Accounts Receivable | $908.21 Million | 12.0% |
| Inventory | $1.30 Billion | 17.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $213.84 Million | 2.8% |
| Goodwill | $196.20 Million | 2.6% |
Asset Composition Trend (1998–2025)
This chart illustrates how Biomarin Pharmaceutical Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BMRN stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomarin Pharmaceutical Inc's current assets represent 52.1% of total assets in 2025, an increase from 40.6% in 1998.
- Cash Position: Cash and equivalents constituted 17.3% of total assets in 2025, down from 29.8% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 37.0% in 1998.
- Asset Diversification: The largest asset category is inventory at 17.1% of total assets.
Biomarin Pharmaceutical Inc Competitors by Total Assets
Key competitors of Biomarin Pharmaceutical Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩39.70 Billion |
|
ORUM
KQ:475830
|
Korea | ₩191.52 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
USA | $1.53 Billion |
|
Green Cross Holdings Preference Shares
KO:005257
|
Korea | ₩4.12 Trillion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
|
Cybin Inc
NEO:CYBN
|
Canada | CA$290.11 Million |
Biomarin Pharmaceutical Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.81 | 5.52 | 5.32 |
| Quick Ratio | 4.20 | 3.49 | 3.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.81 Billion | $2.84 Billion | $1.91 Billion |
Biomarin Pharmaceutical Inc - Advanced Valuation Insights
This section examines the relationship between Biomarin Pharmaceutical Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.77 |
| Latest Market Cap to Assets Ratio | 1.44 |
| Asset Growth Rate (YoY) | 8.7% |
| Total Assets | $7.59 Billion |
| Market Capitalization | $10.93 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Biomarin Pharmaceutical Inc's assets above their book value (1.44x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Biomarin Pharmaceutical Inc's assets grew by 8.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Biomarin Pharmaceutical Inc (1998–2025)
The table below shows the annual total assets of Biomarin Pharmaceutical Inc from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.59 Billion | +8.66% |
| 2024-12-31 | $6.99 Billion | +2.15% |
| 2023-12-31 | $6.84 Billion | +7.32% |
| 2022-12-31 | $6.38 Billion | +6.19% |
| 2021-12-31 | $6.00 Billion | +2.66% |
| 2020-12-31 | $5.85 Billion | +24.69% |
| 2019-12-31 | $4.69 Billion | +5.94% |
| 2018-12-31 | $4.43 Billion | -4.45% |
| 2017-12-31 | $4.63 Billion | +15.15% |
| 2016-12-31 | $4.02 Billion | +7.89% |
| 2015-12-31 | $3.73 Billion | +49.75% |
| 2014-12-31 | $2.49 Billion | +10.98% |
| 2013-12-31 | $2.24 Billion | +43.08% |
| 2012-12-31 | $1.57 Billion | +20.11% |
| 2011-12-31 | $1.31 Billion | +3.41% |
| 2010-12-31 | $1.26 Billion | +37.67% |
| 2009-12-31 | $917.16 Million | +1.15% |
| 2008-12-31 | $906.70 Million | +11.21% |
| 2007-12-31 | $815.28 Million | +75.92% |
| 2006-12-31 | $463.44 Million | +137.29% |
| 2005-12-31 | $195.30 Million | -16.17% |
| 2004-12-31 | $232.97 Million | -9.12% |
| 2003-12-31 | $256.34 Million | +131.74% |
| 2002-12-31 | $110.62 Million | -35.62% |
| 2001-12-31 | $171.81 Million | +123.33% |
| 2000-12-31 | $76.93 Million | -25.70% |
| 1999-12-31 | $103.55 Million | +228.62% |
| 1998-12-31 | $31.51 Million | -- |
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV t… Read more